|
 |
| home > epc > winter 2001 > a competitive analysis of the japanese pharmaceutical and biotechnology industries |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
At the time of writing, Taisho Pharmaceutical Co Ltd and Tanabe Seiyaku Co Ltd have announced a merger under the tentative name of Taisho Tanabe Pharma Group. Both companies were in the top tier of Japanese pharmaceutical companies, with sales of 274 billion yen and 194 billion yen respectively, for the financial year end of March 2001. The question that now arises from the rhetoric of the Japanese pharmaceutical market is: does the merger mark the new beginning of the long awaited consolidation of the Japanese market? Or, is this a one-off event within the industry and what prospects exist for other Japanese pharmaceutical companies?
Japan is always described in any pharmaceutical journal as being the second largest pharmaceutical market in the world. Combine this with the prospect of a population of 127 million people, a drug expenditure of £355 per head, and the fastest ageing population in the world, and you have a market that is ripe for picking.
So why is there such a limited presence of foreign pharmaceutical companies in the marketplace and why are Japanese pharmaceutical companies so worried about their future prospects?
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
